BioSpace News Archive

Dan Kastner , USA , has described an entirely new group of rare autoinflammatory diseases. His discoveries have brought new knowledge and led to the development of effective treatments.

Intramuscular injection PLEGRIDY (peginterferon beta-1a) is now approved in the U.S. and the European Union, offering individuals with relapsing multiple sclerosis (MS) a treatment option with significantly reduced injection site reactions PLEGRIDY has a well-characterized safety and efficacy profile with a proven ability to reduce relapses and delay disability progression

Arcutis today announced positive topline results from the DERMIS-1 and DERMIS-2 pivotal Phase 3 studies evaluating roflumilast cream (ARQ-151) as a potential topical treatment for plaque psoriasis.

Graybug Vision, Inc., a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, announced the appointment of Bettina Maunz as Chief People Officer.

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has established a clinical research program for the treatment of stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”), a known psychedelic compound that is part of the tryptamine family

Eli Lilly and Company (NYSE: LLY) has partnered with local health systems to launch dedicated infusion center locations serving central, northern, and now southern Indiana that are intended to provide Hoosiers with access to important COVID-19 treatments. Multiple neutralizing antibody therapies, administered via intravenous inf

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has been awarded a contract with UroGPO , the largest Group Purchasing Organization for urology private practice clinics in the US, whose members represent 650 urology group practices and 167 ambulatory surgery centers with more than 3,400 u

Welsh, Carson, Anderson & Stowe (“WCAS”), a leading private equity firm focused exclusively on the healthcare and technology industries, announced today that it is committing up to $250 million to a strategic partnership with Kiniciti, a newly-formed platform.

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potency and specificity for the human kappa-opioid receptor (“KOR”).

OTC – CELZ) Creative Medical Technology Holdings, Inc. announced today new data demonstrating that administration of ImmCelz® to animals with a variety of conditions results is a significant surge of the protein hepatocyte growth factor (HGF-1).